Alex Avila
About Alex Avila
Alex Avila serves as the VP and Head of US Medical Affairs at Kite Pharma, where he has worked since 2021. He has extensive experience in oncology and immunotherapy, with a strong focus on melanoma research from his previous roles at Bristol-Myers Squibb and Merck.
Work at Kite Pharma
Alex Avila has served as the Vice President and Head of US Medical Affairs at Kite Pharma since 2021. In this role, he oversees medical strategies and initiatives within the organization, contributing to the advancement of innovative cancer therapies. His position is based in Santa Monica, California, where he has been instrumental in aligning medical affairs with Kite's mission to develop transformative therapies for patients.
Previous Experience at Bristol-Myers Squibb
Prior to joining Kite Pharma, Alex Avila held multiple roles at Bristol-Myers Squibb. He worked as the US Medical Affairs Melanoma Research Lead from 2014 to 2016 and later as the Oncology Clinical Development lead for Relatlimab (Anti-LAG-3) from 2018 to 2019. His tenure included responsibilities in medical affairs for melanoma, GU, GBM, and early assets, showcasing his extensive involvement in oncology research.
Education and Expertise
Alex Avila holds a Master of Business Administration (MBA) from Fundação Dom Cabral, where he focused on organizational change and sustainable growth. He earned his Medical Doctor (MD) degree from Universidade Federal de Minas Gerais and completed a Ph.D. at Fundação Antônio Prudente. His educational background, combined with his expertise in oncology and immunotherapy, positions him as a knowledgeable leader in medical affairs.
Career Progression and International Experience
Alex Avila has demonstrated significant career progression, transitioning from roles focused on thoracic oncology at Merck to a leadership position at Kite Pharma. His professional journey includes international experience, having worked in both the United States and Brazil. This diverse background enhances his perspective in medical affairs and contributes to his effectiveness in addressing global healthcare challenges.
Research and Development Contributions
During his time at Bristol-Myers Squibb, Alex Avila played a key role in the development of Relatlimab (Anti-LAG-3), an innovative immunotherapy treatment. His involvement in cutting-edge research highlights his commitment to advancing cancer therapies and improving patient outcomes. His background in melanoma research further underscores his contributions to the field.